MHRA (UK)
OTHER
Radiofrequency (RF) Safety Considerations for Wireless Cardiotocography (CTG) Monitoring Systems (DSI/2026/012)
Published: 9/17/2026Detected: 9/17/2026
Summary preview
Introduces heightened MHRA safety expectations for wireless cardiotocography (CTG) monitoring systems using RF telemetry channels, focusing on risks of signal crossover, erroneous CTG traces, and signal dropouts.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountcardiology
pediatrics
clinical
safety
quality
manufacturing
labeling
#MHRA
#wireless CTG
#radiofrequency telemetry
#signal crossover
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/4811/12/2026
- Field Safety Notices from 02 to 06 November2026.11/10/2026
- Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/5mL, EL(26)A/4611/5/2026
- Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/4711/5/2026
- Field Safety Notices: 26 to 30 October 202611/4/2026